For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Influenza A is one of 3 types of influenza viruses (A, B, and C). This virus is composed of two main types of glycoproteins that are located on the surface of the viral envelope. Influenza A virus has one of sixteen possible Hemagglutinin surface proteins and one of nine possible Neuraminidase surface proteins which ultimately causes influenza in birds and some mammals. The primary function of a nucleoprotein (NP) is to encapsidate the negative strand viral RNA for the purpose of RNA replication, transcription and packaging.
|Assay Target||Influenza A NP|
|Assay Target Class||Protein|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||100 Assay Points|
Drug Repurposing can be an effective way to identify treatments for diseases, especially when time is of the essence.
Research scientists at National Center for Advancing Translational Sciences (NCATS), a part of the NIH, embarked on a drug repurposing strategy as the quickest route to generating data that would help the pharma industry drive towards an effective treatment for the COVID-19 virus.
Find out how in a matter of months the NCATS team was able to screen 3,384 molecular entities and narrow them down to a field of 25 quality "hits" capable of disrupting SARS-Cov-2 S1 protein:ACE2 receptor binding in this case study.